
Vitamin K antagonist - Wikipedia
Vitamin K antagonists (VKA) are a group of substances that reduce blood clotting by reducing the action of vitamin K. The term "vitamin K antagonist" is technically a misnomer, as the drugs do not directly antagonize the action of vitamin K in the pharmacological sense, but rather the recycling of vitamin K. Vitamin K antagonists (VKAs) have ...
华法林和其他维生素K拮抗剂的用法用量和副作用 - UpToDate
2024年1月31日 · 华法林和其他维生素K拮抗剂(vitamin K antagonist, VKA,也称香豆素类,如醋硝香豆素、苯丙香豆素、氟茚二酮)已应用数十年,用途广泛。 其治疗范围窄,所以使用起来难度大,而且用法用量受到多种因素的影响,包括遗传变异、药物间相互作用和饮食。
Patient self-management of oral anticoagulation with vitamin K ...
Patient self-management (PSM) of vitamin K antagonists (VKA) seems a very promising model of care for oral anticoagulation in terms of efficacy and safety. In comparison with other management models of VKA therapy, the number of scientific ...
For patients receiving maintenance VKA therapy for treatment of VTE, the ASH guideline panel recommends using patient self-management (PSM), where patients perform point-of-care international normalized ratio
Therapy with direct oral anticoagulants for secondary prevention …
2024年10月23日 · After a comprehensive literature search, this systematic review and meta-analysis summarises all available RCTs for the use of secondary prophylaxis with DOACs versus VKA in patients with APS, including the latest ASTRO-APS Study. We found no clinical value in choosing DOACs over VKA for secondary thrombosis prophylaxis in patients with APS.
[臨床藥學] 口服抗凝血藥品選擇完全攻略 ... - NEJS
目前使用的NOAC都需要根據腎功能調整劑量,且在肌肝酸廓清率 (Clcr) 低於30 mL/min,並不建議使用。 ARISTOTLE研究中,排除Clcr低於25 mL/min的病人,但美國FDA仍然根據少數藥物動力學研究核准了嚴重腎功能不全或透析病人的劑量。
Pharmacology and Management of the Vitamin K Antagonists
In patients beginning vitamin K antagonist (VKA) therapy, we recommend the initiation of oral anticoagulation with doses between 5 mg and 10 mg for the first 1 or 2 days for most individuals, with subsequent dosing based on the international normalized ratio (INR) response (Grade 1B).
Treatment of venous thromboembolism with vitamin K antagonists ... - PubMed
Determining the optimal duration of vitamin K antagonist (VKA) therapy for patients with venous thromboembolism (VTE) requires a weighting of the benefits and risks of treatment. The objectives of our study were to investigate patient variability in health state valuations associated with VKA therap …
Pharmacology and management of the vitamin K antagonists ... - PubMed
It describes the antithrombotic effect of the VKAs, the monitoring of anticoagulation intensity, and the clinical applications of VKA therapy and provides specific management recommendations. Grade 1 recommendations are strong and indicate that the benefits do or do not outweigh the risks, burdens, and costs.
VKA30 | VKA30CF | Parker Ermeto | Blanking plug for cones with O …
Wide range of Ermeto fittings, adapters, rotary fittings, weld fittings from Parker. Over 30.000 items ranging across multiple product lines and categories in stock. See all items Online!